Interdisciplinary Centre for Bioinformatics (IZBI), Leipzig University, Leipzig, Germany.
Laboratory for Transplantation Immunology, University Hospital Leipzig, Leipzig, Germany.
Front Immunol. 2024 May 22;15:1384823. doi: 10.3389/fimmu.2024.1384823. eCollection 2024.
In a cooperative study of the University Hospital Leipzig, University of Leipzig, and the Charité Berlin on kidney transplant patients, we analysed the occurrence of HLA-specific antibodies with respect to the HLA setup of the patients. We aimed at the definition of specific HLA antigens towards which the patients produced these antibodies.
Patients were typed for the relevant HLA determinants using mainly the next-generation technology. Antibody screening was performed by the state-of-the-art multiplex-based technology using microspheres coupled with the respective HLA alleles of HLA class I and II determinants.
Patients homozygous for *********, and * in the class I group and **********, and * in the class II group were found to have a significant higher antibody production compared to the heterozygous ones. In general, all HLA determinants are affected. Remarkably, * homozygous patients can produce antibodies towards all HLA-A determinants, while * homozygous ones make antibodies towards all HLA-B and selected HLA-A and C antigens, and are associated with an elevation of , and * seems to increase the risk for antibody responses against most of the HLA class I antigens (HLA-A, HLA-B, and HLA-C) in contrast to * where a lower risk towards few HLA-A and HLA-B alleles is found. The widely observed differential antibody response is therefore to be accounted to the patient's HLA type.
Homozygous patients are at risk of producing HLA-specific antibodies hampering the outcome of transplantation. Including this information on the allocation procedure might reduce antibody-mediated immune reactivity and prevent graft loss in a patient at risk, increasing the life span of the transplanted organ.
在莱比锡大学医院、莱比锡大学和柏林夏里特医院的一项合作研究中，我们分析了肾移植患者 HLA 特异性抗体的发生情况，以了解患者的 HLA 配型。我们旨在确定患者产生这些抗体所针对的特定 HLA 抗原。
使用主要的下一代技术对患者进行相关 HLA 决定簇的分型。使用基于微球的最先进的多重技术进行抗体筛选，微球与 HLA Ⅰ类和Ⅱ类决定簇的相应 HLA 等位基因结合。
在 HLA Ⅰ类群体中，纯合子 ****** 和 ****** 的患者与杂合子相比，抗体产生显著更高。一般来说，所有 HLA 决定簇都会受到影响。值得注意的是，**** 纯合子患者可产生针对所有 HLA-A 决定簇的抗体，而 **** 纯合子患者可产生针对所有 HLA-B 和选定的 HLA-A 和 C 抗原的抗体，并与升高的 和 相关，而 **** 似乎增加了对大多数 HLA Ⅰ类抗原（HLA-A、HLA-B 和 HLA-C）产生抗体反应的风险，与 **** 相比，**** 发现对少数 HLA-A 和 HLA-B 等位基因的风险较低。因此，广泛观察到的差异抗体反应归因于患者的 HLA 类型。
纯合子患者有产生 HLA 特异性抗体的风险，从而影响移植的结果。在分配程序中纳入这些信息可能会减少抗体介导的免疫反应，并防止处于风险中的患者发生移植物丢失，从而延长移植器官的寿命。
